Notes: May 16, 2013 -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has notified the New York Stock Exchange (NYSE) of its intention to voluntarily delist its $2 Convertible Preferred Stock (the “Preferred Stock”) from the NYSE. The company’s decision to delist the Preferred Stock was driven by the low number of shares outstanding, low daily trading volume, listing fees and compliance administration costs. Currently, 5,064 shares of Preferred Stock remain outstanding, which is below the minimum number of shares specified by Section 802.01 of the NYSE Listed Company Manual. The company expects to file an application on Form 25 to notify the Securities and Exchange Commission of its withdrawal of the Preferred Stock from listing on the NYSE on or about May 28, 2013. The company expects the delisting of its Preferred Stock to become effective on or about June 10, 2013. The company does not intend to re-list the Preferred Stock on another securities exchange, but expects that the Preferred Stock will be quoted on one or more over-the-counter markets. Delisting the Preferred Stock from the NYSE will not affect its terms, including dividend payments. The company intends to maintain the Preferred Stock’s registration under the Securities Exchange Act of 1934, as amended. The Company will continue to maintain the listing of its common stock on the NYSE.